Navigation Links
Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
Date:8/31/2009

CHADDS FORD, Pa., Aug. 31 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it will present at the Thomas Weisel Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer of Endo, will review the company's products and development programs.

The presentation will be webcast live and can be accessed from Endo's website at www.endo.com under the investors section.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM((R)), a topical patch to relieve the pain of postherpetic neuralgia; Percocet((R)) and Percodan((R)) tablets for the relief of moderate-to-moderately severe pain; FROVA((R)) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA((R) )tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA((R)) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren((R) )Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; SANCTURA((R)) and its XR version for treatment of overactive bladder; VANTAS((R)) for the palliative treatment of advanced prostate cancer; and SUPPRELIN((R)) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
2. Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs
3. Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
4. AUDIO from Medialink, Boehringer Ingelheim Pharmaceuticals, Inc. & Pfizer Inc.: Coping with Chronic Obstructive Pulmonary Disease (COPD)
5. Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals
6. Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready-to-Use IV Bags
7. Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
8. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
9. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Baird Healthcare Investor Conferences on September 9 and September 10, 2009
11. Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP ... today that Karen Pilley has been promoted to Chief Executive Officer. , ... healthcare paradigm – a shift that demands the transition from pay-for-service to pay-for-performance ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for more ... Program (HRRP), the return of a patient to the hospital within 30 days of ... providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has saved ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati ... years of research, development and clinical trials, the founder of Chigurupati Technologies has ... compound of FDA approved ingredients that when infused into alcohol, protect the consumer’s ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection of ... care, NWH has achieved Magnet® recognition for the second time, announced ... The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... DUBLIN , Feb. 17, 2017 ... ("Theravance Biopharma" or the "Company") today announced the ... novel, potent, and orally administered pan-Janus kinase (JAK) ... 12 th Congress of the European Crohn,s ... the Company reported further data from its completed ...
(Date:2/17/2017)... Research and Markets has announced the addition of the "Drug-Eluting ... ... for the US, Canada , Japan ... Latin America , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
Breaking Medicine Technology: